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Edited by Felix WielandAbstract In ElasCCK2 transgenic mice expressing cholecysto-
kinin (CCK2) receptor in acinar cells, pancreatic phenotypic
alterations and preneoplastic lesions are observed. We deter-
mined whether activation of phospholipase C gamma1 (PLCc1),
known to contribute to the tumorigenesis pathophysiology, could
take place as a new signaling pathway induced by the CCK2
receptor. Overexpression and activation of the PLCc1 in
response to gastrin was observed in acinar cells. The possibility
that the C-terminal tyrosine 438 of the CCK2 receptor associ-
ates with the SH2 domains of PLCc1 was examined. A speciﬁc
interaction was demonstrated using surface plasmon resonance,
conﬁrmed in a cellular system and by molecular modeling.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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We recently demonstrated that transgenic expression of the
cholecystokinin (CCK2) receptor (CCK2R), a G-protein-
coupled receptor (GPCR), in pancreatic acini of ElasCCK2
mice stimulates pancreatic growth and induces phenotypic
changes and tumorigenesis [1]. Molecular mechanisms leading
to these eﬀects are unresolved but logically result from the
introduction of the CCK2 receptor on a CCK1 receptor
background and its activation by post-prandial release of
gastrin, its speciﬁc ligand. Signaling pathways speciﬁc of the
CCK2R may contribute to the observed changes. Indeed, it is
well established that gastrin modulation of cellular growth,
diﬀerentiation and adhesion is linked to multiple signaling
systems, that depend or not on G-protein coupling, including* Corresponding author. Fax: +33-5-61-32-24-03.
E-mail address: dufresne@toulouse.inserm.fr (M. Dufresne).
1 Both these authors equally contributed to this study.
Abbreviations: PLCc1, phospholipase C gamma1; HA, hemagglutinin-
A; CCK, cholecystokinin; GPCR, G-protein-coupled receptor; ITIM,
immunoreceptor tyrosine-based inhibition motif
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doi:10.1016/j.febslet.2004.05.012phospholipase C (PLC)b and PKC activation, Ca2þ mobili-
zation and induction of several kinases activity [2].
An additional possibility is that CCK2R intrinsic speciﬁci-
ties may also be responsible. Analysis of the CCK1 and CCK2
receptor protein sequences shows the presence of consensus
immunoreceptor tyrosine-based inhibition motif (ITIM) [3] in
the C-terminal intracellular cytoplasmic tail as well as in the
third intracellular loop. Tyrosine residues of the ITIM se-
quences are phosphorylable candidate residues that may bind
SH2 domains signaling molecules and initiate alternate signal
transduction cascades. Interestingly, the CCK2R contains one
ITIM sequence in the C-terminal intracellular tail that is ab-
sent in the CCK1R sequence.
We examined whether this phosphorylable tyrosine residue
(Tyr438) would associate with the PLCc1. Indeed, PLCc1 has
been implicated in pathways leading to cellular morphological
changes, migration and proliferation [4]. Several reports also
indicate that PLCc1 is overexpressed in many cancers and may
be implicated in the pathophysiology of tumorigenesis [5,6].
Like PLCbs, PLCc1 acts as an early eﬀector in signal trans-
duction of many growth factors and mitogens, hydrolyzing
phosphatidylinositol 4,5-biphosphate (PIP2) in inositol tri-
phosphate (IP3) and diacylglycerol (DAG). Unlike PLCbs,
PLCc1 may have an additionnal pathway to propagate mito-
genic signals via its SH2, SH3 and PH domains [4].
In this study, we show that CCK2R activates and associates
with PLCc1. Moreover, data from surface plasmon resonance
analysis, mutational analysis and molecular modeling dem-
onstrate that the association implicates the C-terminal Tyr438.2. Materials and methods
2.1. Immunohistochemistry
ElasCCK2 mice, their controls (non transgenic littermates) and
preparation of pancreas for immunohistochemistry studies have pre-
viously been described [1,7]. Immunohistochemistry was done on 5 lm
tissue sections using an indirect immunoperoxidase protocol with a
rabbit polyclonal antibody against PLCc1 (1:1500, Santa Cruz Bio-
technology, Heidelberg, Germany).
2.2. Preparation of isolated acini
Dispersed acini from mice pancreas were prepared by collagenase
dissociation and incubated in Krebs–Ringer HEPES medium, pH 7.4,
with or without the CCK2R agonist, sulfated [Nle11]human gastrin 13,
in the presence of the CCK1R antagonist SR 27897 (1.6 lM) [7] andblished by Elsevier B.V. All rights reserved.
Fig. 1. PLCc1 expression in exocrine pancreas. A: Immunostaining in
control pancreas. B: Immunostaining in ElasCCK2 pancreas (original
magniﬁcation, 40).
Fig. 2. Gastrin activates PLCc1 in ElasCCK2 acinar cells. A: Acinar
90 M. Arnould et al. / FEBS Letters 568 (2004) 89–93solubilized in 50 mM Tris buﬀer, pH 7.4, containing 140 mM NaCl, 1
mM EDTA, 1.5% (w/v) CHAPS (3-([3-cholamidopropyl]dimethylam-
monio)-1-propanesulfonate), 0.1% soybean trypsin inhibitor (w/v) and
0.5 mM orthovanadate.
2.3. Surface plasmon resonance analysis
Surface plasmon resonance experiments were performed on a BIA-
core 3000 instrument (BIAcore AB). The biotinylated peptides con-
taining the CCK2R ITIM sequences (in boldface) (peptide Y238:
FIPGVVMAVAYGLISRELYL, peptide Y390: SYASASVNPLVY-
CFMHRRFRQ, peptide Y438: SIASLSRLSYTTISTLGPG) were
synthesized on chlorotrityl resin by automated SPPS according to the
Fmoc/tBu chemistry. For the synthesis of the phosphotyrosine pep-
tides, Fmoc-Tyr(PO3H2)-OH was used and couplings were performed
with HOBt/HBTU/DIPEA (1:1:2). The biotinylated peptides were
immobilized on streptavidin-coated carboxymethylated dextran chips
[8]. Diﬀerent concentrations of the PLCc1 protein corresponding to
the two SH2 and the SH3 domains (amino acids 530–850 of rat
PLCc1, Santa Cruz Biotechnology, Heidelberg, Germany) were passed
over the immobilized ITIM peptides and kinetic and aﬃnity constants
were determined using BIAevaluation software (BIAcore).
2.4. Site-directed mutagenesis and transfection of COS-7 cells
N-terminal hemagglutinin-A (HA)-tagged wild-type (WT) and ty-
rosine mutated human CCK2R cDNAs were constructed by oligo-
nucleotide-directed mutagenesis [9]. COS-7 cells were transfected with
vectors containing the cDNA for the WT or mutated CCK2R, using a
modiﬁed DEAE–dextran method [10] and incubated with 10 nM
gastrin during indicated times, then solubilized for immunoprecipita-
tion and Western blot studies as previously described [11].
2.5. Receptor binding assays
(Thr,Nle)-CCK-9 was conjugated with Bolton–Hunter reagent and
radioiodinated as described previously [12]. Transfected COS-7 cells
were transferred to 24-well plates, washed with phosphate-buﬀered
saline, pH 6.95, 0.1% BSA and then incubated for 60 min at 37 C with
60 pM 125I-BH-(Thr,Nle)-CCK-9 in the presence or the absence of
competing agonists for binding experiments [10].
2.6. Immunoprecipitation and Western blot analysis
Solubilized acinar proteins (500 lg) were immunoprecipitated with
anti-PLCc1 polyclonal antibody or control IgG (2 lg/ml, Santa Cruz
Biotechnology, Heidelberg, Germany), separated by SDS–PAGE,
blotted on nitrocellulose membranes and probed with anti-phospho-
tyrosine (PY20, Transduction Laboratories) or anti-PLCc1 monoclo-
nal antibody (clone D-7-3, Upstate Biotechnology). Solubilized COS-7
cells proteins (1 mg) were immunoprecipitated with anti-PLCc1
polyclonal antibody or anti-HA antibody (clone 12CA5, Boehringer
Mannheim, IN, USA). Immunoblots were performed with anti-PLCc1
polyclonal antibody or polyclonal anti-HA antibody (Clontech, Palo
Alto, USA). Membranes were incubated with peroxidase-coupled
secondary antibodies (1:10,000, Pierce, Bezons, France) and proteins
were detected using the enhanced chemiluminescence system (Amer-
sham Biosciences) or 125I-protein A [11].
2.7. Molecular modeling
Available NMR structure of the complex comprising the C-terminal
SH2 of PLCc1 and a phosphopeptide from PDGF receptor (residues
1018–1029) was used as template. The C-terminal part of the CCK2R
containing phosphorylated Tyr438 (residues 433–447) was constructed
by homology modeling on the basis of the PDGF receptor phospho-
peptide [13]. Then, CCK2R fragment containing phosphorylated
Tyr438 was docked to C-terminal SH2 domain of PLCc1. This
docking was achieved by manual substitution of the phosphopeptide
from PDGF receptor by modelled CCK2R fragment containing
phosphorylated Tyr438 in the protein complex. Procedures of energy
minimization were then applied. Insight II modules were used (Ho-
mology, Discover and Biopolymer; Accelrys, San Diego, CA, USA).cells were incubated with (+) or without ()) sulfated gastrin (0.1 lM)
during 1 min at 37 C, followed by immunoprecipitation of the cell
lysate with polyclonal anti-PLCc1 antibodies and Western blotting
with anti-phosphotyrosine antibodies. Negative control used rabbit
preimmune serum for immunoprecipitation. B: The same ﬁlters were
stripped and reprobed with monoclonal anti-PLCc1 antibodies. The
data shown are representatives of three independent experiments.3. Results
As shown in Fig. 1 pancreatic acini expressed PLCc1. While
expression was moderate in control pancreas, we found anincreased staining at the inner plasma membrane of ElasCCK2
acini consistent with an overexpression of PLCc1 in these cells.
We next examined whether gastrin treatment would stimu-
late PLCc1 phosphorylation in isolated ElasCCK2 pancreatic
acini. Western blot analysis of proteins immunoprecipitated
with polyclonal anti-PLCc1 antibody shows that a protein
migrating at 143 kDa was phosphorylated following gastrin
(Fig. 2A). This protein was absent in negative control experi-
ments using rabbit preimmune serum for immunoprecipita-
tion. Immunoblotting with monoclonal anti-PLCc1 antibody
yielded staining of a single protein migrating at 143 kDa and
Fig. 3. Surface plasmon resonance analysis of PLCc1 binding to CCK2
receptor ITIM peptides. A: Schematic representation of the CCK2
receptor. The three phosphorylable tyrosine residues (Y238, Y390,
Y438) are localised. The sequences of the synthetic peptides that
contain the ITIM sequences (shown in boldface) and that were bioti-
nylated for surface plasmon resonance experiments are indicated. B:
Sensorgrams obtained for the association of PLCc1 (100 nM) using a
chip either coupled to C-terminal phosphorylated ITIM peptide of the
CCK2 receptor (pY438) or to the same unphosphorylated peptide
(Y438). The extent of association is represented by the diﬀerence in RU
(resonance units) that are measured at the beginning and the end of the
PLCc1 injection. C: Dose-dependent binding of PLCc1 to the C-ter-
minal phosphorylated ITIM peptide. Diﬀerential response represents
phosphorylated tyrosine-dependent binding.
Fig. 4. Interaction between the PLCc1 and the Tyr438 of the CCK2R.
COS-7 cells were transfected or not (NT) with the WT or mutated HA-
tagged CCK2R (Y438F), incubated with (+) or without ()) 10 nM
sulfated gastrin during indicated times and solubilized. A: After im-
munoprecipitation with anti-PLCc1 antibodies, proteins were blotted
with anti-HA and anti-PLCc1 antibodies. B: After immunoprecipita-
tion with anti-HA antibodies, proteins were blotted with anti-PLCc1
and anti-HA antibodies. C: Densitometric analysis of data shown in B.
Results represent means  S.E.M. of three independent experiments. 
and  signiﬁcance at P from 0.01 to 0.05 and P from 0.001 to 0.01,
respectively, determined using the Student’s t test. D: COS-7 cells were
transfected with the double mutated HA-tagged CCK2R (Y238F/
Y438F), incubated with (+) or without ()) 10 nM sulfated gastrin
during indicated times and solubilized. After immunoprecipitation
with anti-PLCc1 antibodies, proteins were blotted with anti-HA
antibodies.
Table 1
Binding characteristics of the WT HA-tagged and mutated CCK2 receptors
Receptor KD1 (nM) KD2 (nM)
WT 0.3 0.1 14.4 1.2
Y438F 0.4 0.1 11.2 1.2
Y238F/Y438F 0.5 0.1 10.6 1.0
Binding parameters (KD and Bmax) were determined by Scatchard analysis (K
Hunter-(Thr,Nle)-CCK9 on COS-7 cells transfected with WT or mutated C
iments. Each experiment was realized in duplicate.
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demonstrate that the CCK2R mediates PLCc1 activation in
ElasCCK2 acinar cells.
The hypothesis of a direct interaction between the CCK2R
and the PLCc1 was then tested using surface plasmonic reso-
nance to assess quantitatively the capacity of the phosphorylatedBmax 1 (pmol/106 cells) Bmax 2 (pmol/106 cells)
1.9 0.7 10.3 0.8
2.6 0.1 15.9 1.7
0.5 0.7 7.2 2.1
ell Radlig software) of binding inhibition experiments of 125I-Bolton-
CK2 receptors. Values are means S.E.M. from three separate exper-
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(Fig. 3A) to interact with SH2 domains of the enzyme. A clear
interaction between the immobilized C-terminal phosphory-
lated ITIM peptide containing Tyr438 and PLCc1 was ob-
served, whereas no bindingwas found for the unphosphorylated
peptide (Fig. 3B) demonstrating that the association speciﬁcally
depends on the phosphorylated tyrosine. Binding of the PLCc1
proteinwas dose-dependent (2–200nM) (Fig. 3C).Global ﬁtting
of these interactions results in anaﬃnity constant of 38 nManda
maximal binding of 985 resonance units. A speciﬁc interaction
between PLCc1 and phosphorylated Tyr238 was also measured
but aﬃnity andmaximal associationwere lower (not shown).No
association was obtained with the phosphorylated Tyr390.
To determine whether the interaction between the CCK2R
and PLCc1 also exists in a cellular context, we performed
immunoprecipitation experiments using COS-7 cells trans-
fected with the N-terminal HA-tagged CCK2R. Cells were
stimulated with gastrin for various times then lysed and the
PLCc1 was immunoprecipitated from the lysates. Immunoblot
with the anti-HA antibody shows that gastrin induced a rapid
and transient association of PLCc1 with the receptor that was
maximal within 1 min (Fig. 4A). This result was conﬁrmed by
performing immunoprecipitation of the CCK2R followed by
anti-PLCc1 blotting (Fig 4B and C). To test the role of C
terminal ITIM site of the CCK2R, and more particularly that
of the phosphorylable tyrosine residue present within this
motif, we replaced Tyr438 with phenylalanine (Y438F).
Binding properties of mutated receptor were similar compared
with WT receptor (Table 1). In contrast, interaction with
PLCc1 in response to gastrin was modiﬁed. Indeed, while
basal association was increased compared to WT, PLCc1 was
unable to interact with the stimulated mutated Y438F CCK2R
(Fig. 4A–C). We then tested the hypothesis that increased
basal association resulted from an interaction with the ITIM
motif located in the third intracellular loop, investigating
whether PLCc1 would associate with a double mutated
Y238F/Y438F CCK2R. This mutant exhibited same binding
characteristics as WT receptor (Table 1). As shown in Fig. 4D,Fig. 5. Interactions between the PLCc1 SH2 domain and the C ter-
minal part of the CCK2R. Molecular surface of the PLCc1 SH2 do-
main is shown in gray. Amino acids of the CCK2R fragment (residues
433–447) interacting with PLCc1 are indicated in red (arrows).double mutation did not abolish basal interaction of PLCc1
with the CCK2R. Taken together, these results demonstrate
the essential role of Tyr438 for PLCc1 association in response
to CCK2R activation.
Interactions between PLCc1 and the CCK2R were further
studied using molecular modeling. In the reﬁned model of
complex obtained, phosphorylated Tyr438 of the CCK2R is
stably inserted into a binding pocket through strong interac-
tions with aminoacids Arg39 and His57 of SH2 domain of
PLCc1 (Fig. 5). These interactions were not found when
Tyr438 was not phosphorylated (data not shown). According
to the model, interaction of CCK2R with SH2 of PLCc1 also
involves residues at positions )1 (Ser437), þ1 (Thr439) and þ6
(Leu444) relative to the Tyr438 residue. Those residues inter-
act, respectively, with Glu22, His57 and Arg91 of PLCc1 SH2
domain (Fig. 5).4. Discussion
The CCK2 receptor is a GPCR that speciﬁcally mediates the
actions of gastrin via association and activation of heterotri-
meric G proteins and activation of many signaling enzymes
such as the PLC, the protein kinases C and A as well as other
kinases involved in the regulation of mitogenesis and cellular
adhesion by growth factors [11,14–16].
Results of the current study show that targeting expression
of the CCK2R in pancreatic acinar cells is associated with
overexpression of PLCc1 in these cells. Increased expression of
PLCc1 is known to occur in pathological situations including
cancer [6] and kidney diseases [17] as well as in benign hy-
perproliferative epidermal diseases [18] but paradoxically,
regulation of PLCc1 expression has not been well character-
ized. In the case of ElasCCK2 mice, overexpression is consis-
tent with eﬃcient activation of the transgenic CCK2R and
coupling to the phosphoinositide signaling [7]. This additional
signaling pathway may initiate many activities contributing to
increased pancreatic growth, phenotypic changes and cancer
[1].
Second, our data are the ﬁrst example of a possible direct
interaction between the CCK2R and an intracellular eﬀector,
PLCc1. These are in line with accumulating literature data
describing association of GPCRs with a wide variety of pro-
teins other than G proteins [19]. Among these proteins, PLCc1
has been described to be recruited via its SH2 domains to the
C-terminus tail of bradykinin B2 [20] and angiotensin II AT1
receptors [21]. Unlike these receptors, the CCK2R exhibits two
consensus binding motifs, identiﬁed as ITIM sequences, that
bind PLCc1 in a tyrosine phosphorylation-dependent manner
as veriﬁed by in vitro surface plasmon resonance studies. In-
terestingly, a direct interaction with high nanomolar binding
aﬃnity, similar to that reported for other eﬀectors binding to
ITIM-bearing molecules [22], is observed with the C-terminal
motif. This association was also conﬁrmed in cells expressing
the CCK2R in response to gastrin activation. The role of the
phosphorylable tyrosine residues of the ITIM motifs was as-
sessed using site-directed mutagenesis as an alternative to the
demonstration of phosphorylated CCK2R that remains an
actual challenge. Mutation of the C-terminal ITIM tyrosine
residue abolished the interaction in response to gastrin thus
giving biological signiﬁcance to in vitro data. Moreover,
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experimental results. Our data show that increased basal
interaction between PLCc1 and the CCK2R-Y438F mutant
does not result from association to phosphorylated Y238F.
Contribution of other parts of the CCK2R, such as rich prolin
sequences interacting with the SH3 domain of PLCc1, or of
scaﬀolding molecules are likely mechanisms to be considered.
Tyrosine phosphorylation of PLCc1 in response to gastrin
was demonstrated resulting in a PLC stimulation mechanism
similar to that of classic growth factor receptors such as the
epidermal growth factor receptor. While the CCK2R lacks
intrinsic tyrosine kinase activity, it activates several kinases,
among them Src family kinases are described as essential for
B2- and AT1-receptors-stimulated PLCc1 activation [20,21].
Moreover, arachidonic acid and phosphatidylinositol 3,4,5-
triphosphate produced upon stimulation by gastrin of phos-
pholipase A2 [23] and PI3-kinase [14], respectively, may also
likely contribute to the activated state of PLCc1 [24].
In conclusion, PLCc1 is at the junction of numerous signal
transduction pathways and activates diﬀerent biological
responses such as DNA synthesis, transformation, cell move-
ment and migration. Therefore, the demonstration of an
upregulation of PLCc1 in ElasCCK2 acini and of its associa-
tion with the CCK2 receptor is an important step towards the
understanding of the changes of proliferation and diﬀerentia-
tion that were observed in the pancreas of ElasCCK2 mice.
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